Pulmonx Corporation was incorporated in California as Pulmonx on December 26, 1995 and re-incorporated in Delaware on December 4, 2013. The company is a commercial-stage medical technology company that provides minimally invasive treatment for patients with severe emphysema, a chronic obstructive pulmonary disease. The company's solutions, consisting of the Zephyr Endobronchial Valve, the Chartis Lung Assessment System and the LungTraX platform, are designed to treat a large number of patients whose medical management has reached the limit, does not want or is not eligible for surgery. The company has subsidiaries in Germany, Switzerland, Australia, the United Kingdom, Italy, France, Hong Kong and Japan.
